Irbesartan Stada (Irbesartan)

Irbesartan selectively blocks AT1 receptors, preventing angiotensin II from causing vasoconstriction, aldosterone release, and sodium‑water retention. This leads to relaxed blood vessels, reduced blood volume, lower blood pressure, and decreased stress on the heart and kidneys.

The appropriate dose of Irbesartan Stada is determined by a qualified prescriber based on the individual’s medical condition, response to therapy, and other medications. Patients should follow the dosing instructions provided by their healthcare professional.

Irbesartan is classified as Pregnancy Category D, indicating evidence of fetal risk. It should be avoided during pregnancy. Limited data are available for breastfeeding, and the drug may pass into breast milk; therefore, use is generally not recommended without medical advice.

To request Irbesartan Stada, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Irbesartan belongs to the ARB class, which blocks angiotensin II receptors, whereas ACE inhibitors block its production. Both lower blood pressure, but ARBs like Irbesartan are less likely to cause a persistent cough. Choice between them depends on patient tolerance, comorbidities, and physician preference.

Irbesartan Stada should be stored below 25 °C in its original packaging, protected from moisture and light. Do not store in a bathroom or near a heat source. Keep the container tightly closed and out of reach of children.

Irbesartan Stada is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

Serious risks include hyperkalemia (elevated potassium levels), acute kidney injury, severe hypotension, and rare cases of angioedema. Patients should be monitored for these conditions, especially when taking other drugs that affect potassium or renal function.

Irbesartan Stada should not be used by individuals with known hypersensitivity to Irbesartan or any ARB, pregnant women, or patients with severe hepatic impairment without medical supervision. Caution is also advised for those with significant renal impairment or high potassium levels.